GeoVax Highlights MVA Platform’s Potential Amid Bundibugyo Ebola Outbreak, Emphasizing Need for Flexible Biodefense Vaccines

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today commented on the rapidly evolving Bundibugyo Ebola virus (BDBV) outbreak in Central Africa and its broader implications for global infectious disease preparedness. The World Health Organization’s declaration of a Public Health Emergency of International Concern (PHEIC) has highlighted gaps in readiness for less common Ebola species, for which no broadly licensed vaccines currently exist.

GeoVax noted that its MVA-based hemorrhagic fever vaccine programs have previously shown encouraging preclinical protection across multiple filoviruses, including Ebola and Marburg. Key findings include single-dose protection against Zaire Ebola virus in non-human primates, protective efficacy against Sudan Ebola virus in multiple models, and significant survival protection against Marburg virus in non-human primate studies. These data support the potential of MVA-based rapid-response vaccines for emerging viral threats.

“These outbreaks collectively reinforce a growing reality: preparedness against one viral strain does not necessarily ensure preparedness against the next,” said David A. Dodd, CEO of GeoVax. “The world is entering an era of continuous infectious disease emergence and re-emergence, where scalable vaccine platforms, diversified manufacturing capabilities, and flexible biodefense infrastructure will become increasingly important.”

Unlike prior outbreaks involving Zaire ebolavirus, the current outbreak involves the Bundibugyo species, exposing limitations in strain-specific strategies. Public health experts emphasize the need for adaptable vaccine technologies. GeoVax believes its MVA-based platform offers advantages including established safety, flexibility for multiple antigens, broad viral family applicability, rapid adaptation, and potential for multivalent single-dose vaccines targeting multiple hemorrhagic fever pathogens simultaneously.

“Outbreaks involving Ebola, mpox, Marburg, hantavirus, and other emerging pathogens collectively reinforce the growing need for platform technologies capable of supporting rapid response against evolving threats,” added Mr. Dodd. “The lessons emerging from the current outbreak extend beyond Ebola itself and increasingly point toward the need for resilient, scalable, geographically distributed vaccine manufacturing capacity and second-source biodefense preparedness.”

GeoVax is advancing GEO-MVA, its MVA-based vaccine candidate targeting mpox and smallpox, designed to support global orthopox preparedness while contributing to domestic U.S.-based MVA manufacturing capability. The pivotal Phase 3 immunobridging study, supported by an expedited regulatory path from the European Medicines Agency, is scheduled to initiate in Q4 2026, with data expected within three months. The company believes MVA-based technologies align with government priorities for supply-chain resilience, domestic manufacturing, flexible platforms, and multi-threat preparedness.

For more information, visit GeoVax Labs.